ARTICLE | Company News
Clementia takeout to bolster Ipsen’s orphan pipeline
March 1, 2019 8:09 PM UTC
Ipsen Group (Euronext:IPN; Pink:IPSEY) will broaden its rare disease pipeline by acquiring Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) for $1 billion up front.
At $25 per share, the deal price is a 67% premium to Clementia's close of $14.94 on Feb. 22, before the deal was announced. Ipsen’s offer includes a $6 per share contingent value right (CVR) tied to Clementia lead compound palovarotene (R667) that is worth $263 million and, if triggered, would bring the total value of the deal to $1.3 billion. ...